Meropenem "thrive" (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

• Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens.
• Complicated urinary tract infections: eradicates resistant Gram‑negative organisms causing pyelonephritis.
• Nosocomial pneumonia: covers multidrug‑resistant strains implicated in hospital‑acquired lung infections.
• Septicemia: rapidly clears bloodstream infections caused by susceptible bacteria.
• Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible organisms.

• Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, thereby blocking the final transpeptidation step of peptidoglycan cross‑linking. This leads to loss of cell‑wall integrity and bacterial lysis, providing a rapid bactericidal effect against a wide range of Gram‑positive and Gram‑negative organisms, including many resistant strains.

Adverse reactions may occur with any intravenous antibiotic. Monitoring and supportive care are recommended.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Headache: transient and usually resolves without intervention.
• Rash: erythematous skin eruption.
• Elevated liver enzymes: transient increase in transaminases.
• Infusion site reactions: pain or phlebitis at the injection site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth.
• Anaphylaxis: acute hypersensitivity reaction requiring immediate treatment.
• Severe neutropenia: marked reduction in white blood cells.
• Renal toxicity: acute kidney injury in susceptible individuals.

Use meropenem with careful clinical assessment and monitoring.

• Renal function assessment: adjust dose in patients with impaired clearance.
• Hepatic monitoring: observe liver enzyme levels during prolonged therapy.
• Seizure risk: avoid in patients with a history of epilepsy unless benefits outweigh risks.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Drug interactions: review concomitant medications for potential interactions.
• Store below 25°C: keep in original packaging, protect from moisture and light.

Meropenem may interact with several agents, requiring vigilance.

Major Interactions (Avoid)

• Valproic acid: meropenem can markedly reduce serum valproate levels, risking seizure breakthrough.
• Other carbapenems: concurrent use may increase toxicity without added benefit.
• High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, monitor INR.
• Oral contraceptives: possible reduction in efficacy, advise alternative contraception.
• Phenytoin: may alter plasma concentrations, monitor seizure control.
• Loop diuretics: monitor renal function and electrolytes.